

CLAIMS

1. Use of trametinib in the manufacture of a medicament for the treatment of a neurodegenerative disease due to neuronal loss or damage, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, amyotrophic lateral sclerosis (ALS, Lou-Gehrig's disease), dementia, vascular dementia, frontotemporal dementia, Lewy body dementia, multiple system atrophy, corticobasal degeneration, progressive supranuclear palsy, Huntington's disease, primary lateral sclerosis, spinal muscular atrophy, progressive bulbar palsy (PBP), progressive muscular atrophy (PMA), pseudobulbar palsy, hereditary spastic paraplegia (HSP) and cerebellar ataxia.
2. The use according to Claim 1, wherein the neurodegenerative disease is to be treated by inducing neuro-regeneration through differentiation of neural stem cells into neurons.
3. The use according to Claim 2, wherein the neurodegenerative disease is to be treated additionally by protection of neural stem cells and neurons against cytotoxicity of amyloid-betas.
4. The use according to Claim 2, wherein the neurons differentiated from neural stem cells are at least one selected from dopaminergic neuron, GABAergic neuron, cholinergic neuron, and motor neuron.
5. The use according to Claim 1, wherein the neurodegenerative disease is Alzheimer's disease.
6. The use according to Claim 1, wherein the neurodegenerative disease is vascular dementia.

7. The use according to Claim 1, wherein the neurodegenerative disease is amyotrophic lateral sclerosis (ALS, Lou-Gehrig's disease).
8. The use according to Claim 1, wherein the neurodegenerative disease is Huntington's disease.
9. Use of trametinib in the manufacture of a medicament for the treatment of Parkinson's disease by inducing neuro-regeneration through differentiation of neural stem cells into neurons.
10. The use according to Claim 9, wherein the neurons differentiated from neural stem cells are dopaminergic neuron.
11. The use according to any one of Claims 1 to 10, wherein trametinib is to be administered 0.1 mg to 2 mg once daily.
12. The use according to Claim 11, wherein trametinib is to be administered 0.1 mg to 1 mg once daily.
13. The use according to Claim 12, wherein trametinib is to be administered 0.1 mg to 0.5 mg once daily.